Margaret H Dohnalek

20080003329, Jan 3, 2008

Jun 30, 2006

11/479504

Ricardo Rueda - Granada, ES
Alejandro Barranco - Las Gabias, ES
Maria Ramirez - Granada, ES
Enrique Vazquez - Ogijares, ES
Eduardo Valverde - Cajar, ES
Pedro Prieto - Columbus OH, US
Margaret H. Dohnalek - Gurnee IL, US

A23L 1/30

426 72

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

20080003330, Jan 3, 2008

Jun 30, 2006

11/479621

Ricardo Rueda - Granada, ES
Alejandro Barranco - Las Gabias, ES
Maria Ramirez - Granada, ES
Enrique Vazquez - Ogijares, ES
Eduardo Valverde - Cajar, ES
Pedro Prieto - Columbus OH, US
Margaret H. Dohnalek - Gurnee IL, US

A23L 1/30

426 72

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

20080057178, Mar 6, 2008

Jun 29, 2007

11/771435

Ricardo Rueda - Granada, ES
Alejandro Barranco - Las Gabias, ES
Maria Ramirez - Granada, ES
Enrique Vazquez - Ogijares, ES
Eduardo Valverde - Cajar, ES
Pedro Prieto - Mexico City, MX
Margaret Dohnalek - Gurnee IL, US

A23J 1/20
A23L 1/305

426656000

Disclosed are infant formulas comprising, on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid is provided by an enriched whey protein concentrate, with the concentrate representing at least about 6.5 g/L of the formula on an as-fed basis. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

20080064635, Mar 13, 2008

Jun 29, 2007

11/771417

Ricardo Rueda - Granada, ES
Alejandro Barranco - Las Gabias, ES
Maria Ramirez - Granada, ES
Enrique Vazquez - Ogijares, ES
Eduardo Valverde - Cajar, ES
Pedro Prieto - Mexico City, ES
Margaret Dohnalek - Gurnee IL, US

A61K 38/16
A23D 7/005
A61P 43/00

514012000, 426601000

Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, and at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, all of which are provided in whole or in part from the enriched whey protein concentrate. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

60369922, Mar 14, 2000

Mar 16, 1999

9/270423

David A. Borror - Westerville OH
David V. Diodato - Hilliard OH
Debra L. Ponder - Morristown NJ
Margaret H. Dohnalek - Worthington OH

Abbott Laboratories - Abbott Park IL

A23J 700
A23L 110
A23L 132

426662

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs) and a process for making such enteral compositions are described. More particularly, the invention relates to enteral compositions which provide long chain PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol and may be derived from egg yolk lipids, and thus are predominantly in a phospholipid form. The process of making such a composition provides improved organoleptic and stability properties. Enteral compositions according to this invention may be used to feed infants, particularly pre-term infants, to promote neural development and development of visual acuity, and to reduce the incidence of necrotizing enterocolitis.

60807873, Jun 27, 2000

Oct 3, 1997

8/943576

Susan E. Carlson - Kansas City MO
Debra L. Ponder - Evansville IN
Michael B. Montalto - Columbus OH
Margaret H. Dohnalek - Worthington OH
John D. Benson - Powell OH
David A. Borror - Westerville OH
David V. Diodato - Hilliard OH

Abbott Laboratories - Abbott Park IL

A61K 31202
A61K 31225
A61K 31685

514560

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), as arachidonic acid (AA) and docosahexaenoic acid (DHA) that are essentially free of cholesterol, are described. More particularly, the invention relates to methods for reducing the incidence of necrotizing enterocolitis by administering compositions which provide. omega. -6 and. omega. -3 long chain PUFAs, phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain. omega. -6 and. omega. -3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergistic effect.

63069083, Oct 23, 2001

May 12, 2000

9/570299

Susan E. Carlson - Kansas City MO
Debra L. Ponder - Evansville IN
Michael B. Montalto - Columbus OH
Margaret H. Dohnalek - Worthington OH
John D. Benson - Powell OH
David A. Borror - Westerville OH
David V. Diodato - Hilliard OH

Abbott Laboratories - Abbott Park IL

A61K 31202
A61K 31225
A61K 31685

514560

Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs), e. g. , arachidonic acid (AA), and docosahexaenoic acid (DHA), essentially free of cholesterol, are described for use in methods for reducing the incidence of necrotizing enterocolitis. Compositions from egg yolk lipids are preferred as they contain. omega. -6 and. omega. -3 long chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergetic effect.

20230060769, Mar 2, 2023

Aug 8, 2022

17/818011

- Eustis FL, US
MARGARET H. DOHNALEK - Mount Dora FL, US
LAWRENCE T. McCARTY - Mount Dora FL, US
ELIZABETH J. CARTWRIGHT - Fruitland Park FL, US

A61K 36/889
A61K 9/00
A61K 9/48
A61K 31/20
A61K 31/201

A dietary supplement composition is formulated in a therapeutic amount to maintain and promote urinary and prostate function in a human. The composition includes a shelf stable, supercritical COfluid extracted, enhanced lipidosterolic extract of (LSESr). The enhanced LSESr has a ratio of free fatty acids to total fatty acids that is greater than about 80.0% and an enrichment of lauric, myristic, oleic and linoleic acids as free fatty acids to total free fatty acids that is greater than about 82.0%.